17,261 trials
Tetanus · Diphtheria · Haemophilus Influenzae Type b
Primary: Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP) — 132; 126; 114 Participants
Secondary Hyperparathyroidism
Primary: Percent Change From Baseline in Parathyroid Hormone (PTH) During the Efficacy Period — -53.6; -55.6; -50.8 percent change
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) — -0.035; 0.066; 0.168; 0.198 Liters — p=<0.0001
Diffuse Large B Cell Lymphoma
Primary: Complete Response — 11 Participants
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Schizophrenia · Schizoaffective Disorder · Major Depression
Primary: Plasma Levels of Triglycerides and Lipoprotein Cholesterol — 155; 182; 12.68; 16.92 mg/dL
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 1.6; 1.9 units on a scale — p=>0.05
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Pathologic Complete Response (PCR) — 28.6; 40.7 percentage of participants
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Lymphoma
Primary: Overall Response Rate (ORR) — 1 Participants
Ovarian Cancer
Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants
Cannabis Use Disorder
Primary: Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements — 0.5795019; 0.5539831 ratio of errors (see OM description)
Non-Hodgkin's Lymphoma
Primary: ORR — 88; 81 percentage of patients